Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 12, 2016. The document serves as a transaction notification regarding a purchase of ordinary shares by a Person Discharging Managerial Responsibilities (PDMR) under the Company's ShareReward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a specific executive transaction rather than a financial results report.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of 16 ordinary shares (8 partnership shares and 8 matching shares) by Mr. S A Hussain, President of Global Pharmaceuticals.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It strictly reports the execution of a share acquisition on July 11, 2016, at a price of £16.7127 per share on the London Stock Exchange.
Investor Verification Points
- Verify the identity of the PDMR: Mr. S A Hussain, President, Global Pharmaceuticals.
- Confirm the transaction date: July 11, 2016.
- Confirm the transaction price: £16.7127 per share.
- Confirm the total volume: 16 ordinary shares.
- Note that this filing does not contain quarterly or annual financial performance data.